MedTrace Logo

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

NCT04096950 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-05-15

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.

Conditions

  • Spinal Cord Injury

Interventions

BIOLOGICAL

MT-3921 Low dose

MT-3921 Low dose, intravenous, single dosing

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma America Inc.

    lead INDUSTRY

Principal Investigators

  • Head of Clinical Development, · Mitsubishi Tanabe Pharma America Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-19
Primary Completion
2021-01-06
Completion
2021-01-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04096950 on ClinicalTrials.gov